Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EPS (Weighted Average and Diluted) (2021 - 2025)

Benitec Biopharma has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$0.26 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.26 for Q4 2025, down 30.0% from a year ago — trailing twelve months through Dec 2025 was -$0.93 (down 29.17% YoY), and the annual figure for FY2025 was -$1.05, up 13.93%.
  • EPS (Weighted Average and Diluted) reached -$0.26 in Q4 2025 per BNTC's latest filing, down from -$0.22 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.11 in Q2 2024 and bottomed at -$36.27 in Q2 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.59 (2021), compared with a mean of -$3.3.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 3940.32% in 2022 before it skyrocketed 95.85% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.59 in 2021, then plummeted by 466.1% to -$3.34 in 2022, then grew by 20.96% to -$2.64 in 2023, then skyrocketed by 92.42% to -$0.2 in 2024, then dropped by 30.0% to -$0.26 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BNTC at -$0.26 in Q4 2025, -$0.22 in Q3 2025, and -$0.21 in Q2 2025.